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Abstract: Obstructions of the Fallopian tube represent one 
of the most common reasons for an unfulfilled desire to have 
children. Microstent technology opens up new therapeutic 
possibilities to restore the natural lumen of the Fallopian tube 
within a single treatment. Within the current work we 
developed a self-expandable biodegradable microstent for 
gynecological applications. Based on a novel microstent 
design, prototypes were manufactured from poly-L-lactide 
tubing by means of fs-laser cutting. Microstent prototypes 
were characterized morphologically by means of scanning 
electron microscopy and biaxial laser scanning. As 
manufactured, a microstents outside diameter of about 
2.3 mm and a strut thickness / width of about 114 µm / 
103 µm was measured. Mechanical characterization of 
microstents included bending as well as crimping and release 
behavior. After crimping to a minimum diameter of 0.8 mm 
and consecutive release, a microstent recovery to a diameter 
of 1.8 mm was found. Therefore, proof-of-concept for the 
self-expandable microstent could be successfully provided.  
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1 Introduction 
In about 35% of cases, female sterility arises from obstruc-
tions of the Fallopian tube, particularly proximal tube occlu-
sions (PTO) [1]. The Fallopian tube as a hormone-dependent 
valve is responsible for transport of the ovum. Therefore, an 
intact mobility of the fimbrial funnel as well as complete 
patency is crucial. The proximal end of the Fallopian tube is 
formed by longitudinal folds of the mucous membrane with a 
small lumen. Tubal disorders are commonly related to 
congenital anomalies, acute or chronic inflammatory 
diseases, endometriosis and other pathologies resulting in 
partial or total PTO [2]. We developed a therapy concept 
based on a biodegradable self-expandable microstent (Fig. 1). 
Figure 1: Concept of a biodegradable self-expandable microstent 
for minimally invasive treatment of Fallopian tube occlusions:  
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Current treatment options include in vitro fertilisation (IVF) 
or minimally invasive transcervical catheterisation of the 
Fallopian tube as an alternative to the more risky surgery. 
Success rates of conventional treatment options range 
between only 20% to 50% for a subsequent pregnancy [3]. 
Therefore, our biodegradable self-expandable micro-
stent for minimally invasive treatment of Fallopian tube 
occlusions represents a promising treatment option. The 
implant device should restore the patency of the Fallopian 
tube by overcoming the external stenosis (e.g. due to fibrosis) 
and restore the tubal valve function. Within the current study, 
feasibility of the microstent concept was analyzed. 
2 Materials and methods 
2.1 Microstent design 
General requirements of the microstent include biocompa-
tibility and degradation within a time frame of approximately 
two years. For a minimized influence of the device on the 
Fallopian tube epithelium, the stent structure should be 
designed as flexible as possible with a low surface coverage 
of less than 15%. Microstent design was developed using 3D-
CAD (computer-aided design) software Creo Parametric 5.0 
(PTC Inc., USA), considering anatomical boundary con-
ditions as well as manufacturing-relevant aspects (Tab. 1).  
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20.0 mm 2.0 mm / 2.2 mm 100 μm 100 μm 
Figure 2 shows the open-cell design of the microstent. The 
device is composed of 12 meander ring segments, each 
ls = 1.7 mm and u = 6.6 mm wide in longitudinal and 
circumferential direction. Eight meanders are arranged over 
the circumference, per ring segment respectively. 
Longitudinally, the meander ring segments were joint by four 
connector elements, respectively. 
The microstent design (Fig. 2 ) represents the ex-
panded state and offers extensive reserves for diameter re-
duction. To avoid plastic deformations during the crimping 
process, the design was optimized with regard to minimized 
strain amplitudes. The corresponding finite-element analyses 
were not described within the current work. In the expanded 
state, minor surface coverage of 13% was achieved. 
Figure 2: Two-dimensional representation of the microstent  
design (A) and the corresponding 3D-CAD model in the expanded 
state, which represents the microstent configuration as 
manufactured (B). 
2.2 Manufacturing of microstent-
prototypes 
Poly(L-lactide) (PLLA, Resomer L210, Evonik Health Care 
GmbH, Germany) was used as base material. PLLA 
represents an absorbable thermoplastic polymer which is 
widely used in biomedical applications and offers favourable 
mechanical properties in the field of stent technology, such as 
a high elastic modulus of 1,200 MPa ≤ E ≤ 2,700 MPa, a 
tensile strength of 28 MPa ≤ σm ≤ 50 MPa and an elongation 
at break of εB = 6%. Absorption rates of 1.5 to 5 years are 
described in the literature [4]. 
For the manufacturing of tubular semifinished 
products, a solution of 4 g PLLA in 400 ml chloroform (Carl 
Roth GmbH + Co. KG, Germany) was prepared. The dipping 
process is carried out using a self-developed dipping robot. 
During repeated immersion in the solution, the dipping 
mandrels (dm = 2.0 mm) are rotated by 180° per dipping 
repetition, thus achieving a homogeneous distribution of 
tubing wall thickness. Measurement of the tubing outside 
diameter was conducted by means of a biaxial laser system 
(ODAC 32 XY, ZUMBACH Electronic AG, Switzerland). 
Manufacturing of microstent prototypes was conducted 
using a 780 nm fs-laser (Spectra-Physics, Santa Clara, USA) 
in combination with a positioning system (Aerotech 
Laserturn 5, Aerotech, Inc., USA). A laser pulse of 50 fs and 
a repetition rate of 1 kHz with a pulse energy of up to 3.5 mJ 
was used. 
Scanning electron microscopy (SEM, Quattro S, 
Thermo Fisher Scientific Inc., USA) was used to evaluate 
surface and edge quality of the microstent prototypes. 
Imaging was conducted in low vacuum mode without sample 
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preparation by means of conductive layers at a pressure of 
50 Pa and an acceleration voltage of 5 kV. 
Microstent outside diameter was measured optically by 
means of the biaxial laser system in increments of 0.02 mm 
along the longitudinal axis.  
2.3 In vitro testing of microstent 
prototypes 
For mechanical characterization of microstent prototypes, 
bending stiffness and radial force were investigated at 37 °C. 
For determination of the bending stiffness EI, the microstent 
prototypes were clamped on the one side and the free end 
was deflected laterally for u = 300 µm. A clamping length of 
lc = 9 mm was used. Bending reaction force Fb on five 
circumferential positions was measured using an integrated 
load cell (PW4MC3/300G-1, Hottinger Baldwin Mess-
technik, Germany). For each circumferential position three 
force values were recorded and averaged. Bending stiffness 





   (1) 
Radial force Fr as a function of diameter d was measured in 
accordance with DIN EN ISO 2539-2 using the Blockwise 
Radial Force Tester TTR 2 in combination with an iris 
diaphragm (J-Crimp Station RJU124, Blockwise Engineering 
LLC, USA). Crimping was conducted subsequently in 
increments of 0.1 mm to minimum crimping diameters 
ranging from dc = 2.2 mm to 0.8 mm. 
3 Results 
3.1 Manufacturing of microstent 
prototypes 
Tubular semifinished products with reproducible wall 
thickness of t = (97.2 ± 6.0) µm (n = 8) were manufactured. 
Further processing resulted in two microstent prototypes. As 
manufactured, a microstent outside diameter of 
do = (2.35 ± 0.08) mm and do = (2.28 ± 0.06) mm with a 
minor variation along the longitudinal axis was measured for 
prototype #1 and #2, respectively. Strut width and wall 
thickness of approximately ws = 114 μm and t = 103 µm were 
determined at different measuring points using SEM. An 
exemplary macro and a SEM image of microstent prototype 
#2 are shown in Fig. 3.  
Figure 3: Exemplary macro (A) and SEM image (B) of microstent 
prototype #2.  
3.2 In vitro testing of microstent 
prototypes 
The maximum bending reaction force Fb at maximum lateral 
deflection of u = 300 µm and the bending stiffness EI as 
results of the bending tests are summarized in Tab. 2.  
Table 2: Results of bending tests with two microstent prototypes: 
maximum bending reaction force Fb at maximum lateral deflection 
of u = 300 µm and bending stiffness EI based on five 
circumferential measurement positions (n = 3), respectively. 
microstent prototype Fb [N] EI [Nmm²] 
#1 5.40 ± 0.57  1.09 ± 0.19  
#2 5.30 ± 0.63  1.07 ± 0.25  
 
Radial force measurements were conducted using prototype 
#1. Figure 4 depicts the relation of radial force Fr and 
diameter d, exemplary for minimum crimping diameters of 
dc = 2.0 mm, 1.5 mm and 1.0 mm.  
Figure 4: Radial force Fr as a function of diameter d for minimum 
crimping diameters dc = 2.0 mm, 1.5 mm and 1.0 mm; 
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The maximum radial force increases from Fr = 0.32 N to 
37.14 N with degreasing crimping diameter from 
dc = 2.2 mm to 0.8 mm (Fig. 5). 
Figure 5: Maximum radial force Fr as a function of minimum 
crimping diameter dc; Characterization of microstent prototype #1. 
Figure 6 illustrates the microstent diameter after crimping to 
various diameters and consecutive release. Due to plastic 
strain, the diameter after crimping and release decreases with 
decreasing crimping diameters. Nevertheless, after crimping 
to a diameter of dc = 0.8 mm and consecutive release, the 
microstent still recovers to 1.8 mm, corresponding to an 
acceptable diameter recovery of 77% compared with its 
diameter as manufactured.  
Figure 6: Diameter of microstent prototype #1 after crimping to 
diameters from dc = 2.0 mm to 0.8 mm and consecutive release; 
diameter after crimping and release measured using biaxial laser 
device; mean value ± standard deviation of microstent diameter 
along the longitudinal axis; extrapolation for a further reduction of 
crimping diameter. 
4 Discussion 
The current work represents an initial attempt to develop a 
self-expandable biodegradable microstent for minimally 
invasive treatment of Fallopian tube occlusions. The 
presented technologies are suitable for the manufacturing of 
microstent prototypes with reproducible quality.  
The Microstent prototypes show low values for bending 
stiffness, comparable with commercially available 
biodegadable stents for vascular application such as 
BIOTRONIK Magmaris 3.0/20 (EI = 0.89 Nmm2), Abbott 
Absorb GT1 3.0/18 (EI = 4.20 Nmm2) or Elixir DESolve 
3.0/18 (EI = 1.50 Nmm2) [5]. Commercially available drug-
eluting stents for vascular application such as BIOTRONIK 
Orsiro 3.0/15 (EI = 8.8 Nmm²) are commonly by one order of 
magnitude stiffer [6].  
The presented analyses of crimping and release behavior 
strongly indicate feasibility of a polymeric self-expandable 
microstent for gynecological applications in combination 
with a micro delivery catheter with an inner diameter of 
0.8 mm. Further investigations are planned with regard to 
simulated use in an in vitro and ex vivo model. 
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